Breast oncology Clinical Trials in Chicago, IL

As of July 2026, 61 paid clinical trials are recruiting for Breast oncology in Chicago, Illinois. Breast oncology research tests new hormone therapies, HER2-targeted agents, PARP inhibitors, antibody-drug conjugates, and immunotherapy combinations across early-stage and metastatic disease. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 17, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

63 clinical trials for Breast oncology

·Clear filters·↓ Download CSV

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

for Breast Cancer

Sites in Chicago +2 more locations

Sponsor: University of Illinois at Chicago

Sex: All·Age: 18+

Code: NCT06169371·Phase 4·Recruiting·Listed Dec 2023

Apply to this trial

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

for Estrogen-receptor-positive Breast Cancer

3 locations in Chicago

Sponsor: Northwestern University

Sex: All·Age: 18+

Code: NCT06062498·Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

for Breast Atypical Ductal Hyperplasia

Sites in Chicago +10 more locations

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18 - 55

Code: NCT06184750·Phase 2·Recruiting·Listed Dec 2023

Apply to this trial

ATEMPT 2.0: Adjuvant T-DM1 vs TH

for Breast Cancer

Sites in Chicago +46 more locations

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT04893109·Phase 2·Recruiting·Listed May 2021

Apply to this trial

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

for Breast Cancer

Sites in Chicago +14 more locations

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT04468061·Phase 2·Recruiting·Listed Jul 2020

Apply to this trial

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

for Breast Cancer

Sites in Chicago +6 more locations

Sponsor: Massachusetts General Hospital

Sex: Female·Age: 18+

Code: NCT03990896·Phase 2·Recruiting·Listed Jun 2019

Apply to this trial

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

for Breast Cancer

Sites in Chicago +6 more locations

Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All·Age: 18+

Code: NCT04841148·Phase 2·Recruiting·Listed Apr 2021

Apply to this trial

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

for Breast Cancer

1 location in Chicago

Sponsor: University of Chicago

Sex: Female·Age: 25+·Accepts healthy volunteers

Code: NCT03729115·Recruiting·Listed Nov 2018

Apply to this trial

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care

for Breast Cancer

1 location in Chicago

Sponsor: University of Illinois at Chicago

Sex: Female·Age: 30+

Code: NCT05483283·Recruiting·Listed Aug 2022

Apply to this trial

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

for Metastatic Breast Cancer

Sites in Chicago +11 more locations

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT06099769·Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

for Breast Cancer Screening

Sites in Chicago +8 more locations

Sponsor: University of California, San Francisco

Sex: Female·Age: 30 - 74·Accepts healthy volunteers

Code: NCT02620852·Recruiting·Listed Dec 2015

Apply to this trial

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

for Breast Cancer

Sites in Chicago +10 more locations

Sponsor: Ana C Garrido-Castro, MD

Sex: All·Age: 18+

Code: NCT06533826·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

for Breast Cancer

1 location in Chicago

Sponsor: University of Illinois at Chicago

Sex: All·Age: 18+

Code: NCT06085742·Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

for Triple Negative Breast Cancer

1 location in Chicago

Sponsor: University of Illinois at Chicago

Sex: Female·Age: 18+

Code: NCT04427293·Phase 1·Recruiting·Listed Jun 2020

Apply to this trial

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

for Breast Cancer

1 location in Chicago

Sponsor: University of Illinois at Chicago

Sex: All·Age: 18+

Code: NCT06441890·Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

for Breast Cancer

Sites in Chicago +3 more locations

Sponsor: Ruth O'Regan

Sex: All·Age: 18+

Code: NCT04886531·Phase 2·Recruiting·Listed May 2021

Apply to this trial

PRE-I-SPY Phase I/Ib Oncology Platform Program

for HER2-positive Breast Cancer

Sites in Chicago, Orland Park +5 more locations

Sponsor: QuantumLeap Healthcare Collaborative

Sex: All·Age: 18+

Code: NCT05868226·Phase 1·Recruiting·Listed May 2023

Apply to this trial

Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer

for Breast Cancer

1 location in Chicago

Sponsor: Northwestern University

Sex: Female·Age: All ages

Code: NCT00898131·Recruiting·Listed May 2009

Apply to this trial

Time Restricted Eating During Chemotherapy for Breast Cancer

for Breast Cancer Female

1 location in Chicago

Sponsor: University of Illinois at Chicago

Sex: Female·Age: 25 - 99

Code: NCT05259410·Recruiting·Listed Feb 2022

Apply to this trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

Sites in Chicago, Evanston +37 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06380751·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

for Breast Cancer

Drug: Durvalumab

Sites in Chicago +32 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06103864·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Conditions in Breast oncology (Chicago, IL)

Breast cancer· 47 Metastatic breast cancer· 14 Triple-negative breast cancer· 10 HER2-positive breast cancer· 6 HER2-negative breast cancer· 6